Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
Source: SeekingAlpha
2025-03-31 18:34:45 ET
More on AcelRx Pharmaceuticals
- Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
- AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09
- Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals
- Historical earnings data for AcelRx Pharmaceuticals
- Financial information for AcelRx Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
Talphera Inc.
NASDAQ: TLPH
TLPH Trading
-3.98% G/L:
$0.7577 Last:
53,612 Volume:
$0.743 Open:
TLPH Latest News
March 25, 2026 08:30:00 am
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
March 18, 2026 04:05:00 pm
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
March 02, 2026 08:30:00 am
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
November 12, 2025 04:05:00 pm
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
TLPH Stock Data
$39,152,079
25,309,023
0.41%
12
N/A
Pharmaceuticals
Healthcare
US
San Mateo
